AlloVir, Inc. (ALVR)

AlloVir Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-58.77	-190.42	-168.71	-171.96	-69.78
Depreciation & Amortization	-	0.4	0.72	0.19	0.07
Asset Writedown & Restructuring Costs	-	18.57	-	-	-
Loss (Gain) From Sale of Investments	-1.25	-3.7	-1.08	1.2	0.5
Stock-Based Compensation	26.35	40.78	41.32	43.98	9.43
Other Operating Activities	-8.73	7.89	1.84	0.93	-
Change in Accounts Receivable	0.21	-0.05	-0.11	0.4	0.3
Change in Accounts Payable	-28.86	-2.51	-12.62	20.29	2.73
Change in Income Taxes	-	-0.13	-0.88	1.01	-
Change in Other Net Operating Assets	3.35	4.71	-2.54	-2.34	-4.05
Operating Cash Flow	-67.71	-124.45	-142.05	-106.32	-60.81
Capital Expenditures	-	-	-	-0.03	-0.24
Investment in Securities	95	37.99	-80.48	186.01	-169.26
Investing Cash Flow	95	37.99	-80.48	185.98	-169.5
Issuance of Common Stock	0.02	70.5	127.16	0.23	317.69
Other Financing Activities	-	-	-0.2	-	-25.71
Financing Cash Flow	0.02	70.5	126.96	0.23	291.98
Foreign Exchange Rate Adjustments	-	-	-	-0.04	-0.09
Net Cash Flow	27.32	-15.97	-95.57	79.85	61.58
Free Cash Flow	-67.71	-124.45	-142.05	-106.35	-61.05
Free Cash Flow Per Share	-	-27.51	-42.62	-38.96	-52.20
Cash Income Tax Paid	-	0.22	0.61	-	-
Levered Free Cash Flow	-43.45	-66.18	-83.08	-40.04	-36.03
Unlevered Free Cash Flow	-43.45	-66.18	-83.08	-40.04	-36.03
Change in Net Working Capital	8.91	-5.98	18.12	-21.96	0.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q